Connor, Clark & Lunn Investment Management (CC&L)
LCTX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Lineage Cell Therapeutics LCTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,393
Closed -$11.9K – 1604
2025
Q1 		$11.9K Sell
26,393
-159,515
-86% -$93.6K ﹤0.01% 1381
2024
Q4 		$93.4K Sell
185,908
-5,528
-3% -$4.06K ﹤0.01% 1363
2024
Q3 		$173K Sell
191,436
-16,328
-8% -$15.1K ﹤0.01% 1337
2024
Q2 		$207K Buy
207,764
+1,521
+0.7% +$1.68K ﹤0.01% 1258
2024
Q1 		$305K Buy
206,243
+43,560
+27% +$49.4K ﹤0.01% 1258
2023
Q4 		$177K Sell
162,683
-19,878
-11% -$21.8K ﹤0.01% 1278
2023
Q3 		$215K Sell
182,561
-70,714
-28% -$96.2K ﹤0.01% 1226
2023
Q2 		$357K Buy
253,275
+12,253
+5% +$16.9K ﹤0.01% 1075
2023
Q1 		$362K Sell
241,022
-20,880
-8% -$29.1K ﹤0.01% 969
2022
Q4 		$306K Sell
261,902
-26,397
-9% -$33.3K ﹤0.01% 974
2022
Q3 		$326K Buy
288,299
+152,971
+113% +$225K ﹤0.01% 902
2022
Q2 		$214K Buy
135,328
+123,328
+1,028% +$163K ﹤0.01% 920
2022
Q1 		$18K Buy
+12,000
New +$18.6K ﹤0.01% 1010
2020
Q4 		– Sell
-14,601
Closed -$14K – 980
2020
Q3 		$14K Sell
14,601
-41,940
-74% -$37K ﹤0.01% 907
2020
Q2 		$49K Buy
56,541
+5,823
+11% +$5.13K ﹤0.01% 984
2020
Q1 		$42K Buy
50,718
+28,568
+129% +$28.5K ﹤0.01% 971
2019
Q4 		$20K Buy
+22,150
New +$18.5K ﹤0.01% 906
2019
Q2 		– Sell
-14,000
Closed -$18K – 1037
2019
Q1 		$18K Buy
+14,000
New +$17.4K ﹤0.01% 890
2018
Q1 		– Sell
-111,510
Closed -$210K – 761
2017
Q4 		$210K Sell
111,510
-12,677
-10% -$27.7K ﹤0.01% 719
2017
Q3 		$309K Buy
124,187
+9,601
+8% +$23.8K ﹤0.01% 704
2017
Q2 		$316K Buy
114,586
+92,326
+415% +$258K ﹤0.01% 674
2017
Q1 		$67K Buy
+22,260
New +$63.2K ﹤0.01% 867

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LCTX Position: Q2 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 26,393 shares — an estimated $11.9K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LCTX in Q1 2017 and held it in 22 quarters. The position peaked at $362K in Q1 2023. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 26,393 Lineage Cell Therapeutics shares in Q2 2025, an estimated $11.9K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 22 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Lineage Cell Therapeutics position peaked at $362K in Q1 2023.
  • 129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2025, filed 7 Aug 2025.